Organization
IUCT-Oncopole Toulouse
12 abstracts
Abstract
Phase 1/2 Study of DF1001, a novel tri-specific, NK cell engager therapy targeting HER2, in patients with advanced solid tumors: Phase 1 DF1001 monotherapy dose-escalation results.Org: Centre Léon Bérard, Centre Hospitalier de l'Ardenne - Site de Libramont, Centre Oscar Lambret, Institut Curie, Saint Cloud, France, CHU Liège and Liège University,
Abstract
Very long-term follow-up of rituximab maintenance in young patients with mantle cell lymphoma included in the LYMA trial, a LYSA study.Org: Institut Curie, Saint Cloud, France, Hemato-oncology, IUCT-Oncopole Toulouse, Department of Hemagology, Centre François Magendie,
Abstract
Survival outcomes associated with first-line PCV or temozolomide in combination with radiotherapy in IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma.Org: Paris Brain Institute (ICM), Service de Neurologie 2 Mazarin, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, AP-HP, Sorbonne Université, Lyon HCL,
Abstract
Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors.Org: Massachusetts General Hospital, Department of Experimental Therapeutics, National Cancer Center Hospital East, National Cancer Center Hospital East, Kashiwa, Japan, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, Memorial Sloan Kettering Cancer Center,
Abstract
Relevance of timing intake of everolimus (EVE) combined with adjuvant endocrine therapy (ET) in patients (pts) with high-risk early breast cancer: Results of a sub-study of the UCBG-UNIRAD trial.Org: Surgery Department, Institut Curie, Saint Cloud, France, Universite Paris Cite, Residual Tumor and Response to Treatment, U932 Immunity and Cancer,
Abstract
Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI).Org: Université de Poitiers et Centre Hospitalier Universitaire de Poitiers, INSERM U1313 and CIC 1082, Poitiers, France, Hôpital Haut Leveque, University Hospital, Pessac, France, ECSTRA, Centre de Recherche en Epidémiologie et Statistiques, INSERM UMR 1153, Paris, France, Lille University Hospital, Lille, France, CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France,
Abstract
Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the Recurrence Score in node-positive breast cancer: Independent validation in the PACS-01 trial.Org: Exact Sciences Corporation, Gustave Roussy Cancer Center, Centre Léon Bérard, R&D Unicancer, Alliance for Clinical Trials in Oncology,
Abstract
Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.Org: Institut Claudius Regaud, IUCT-Oncopole Toulouse, The Netherlands Cancer Institute, UMC Utrecht, Molecular Partners,
Abstract
Durvalumab + tremelimumab in biologically selected advanced/metastatic solid tumors.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Centre Leon Berard, Lyon I University, Lyon, France, IUCT-Oncopole Toulouse,
Abstract
Prognostic factors in hormone receptor positive oligometastatic breast cancer.Org: Institut Claudius Regaud (ICR), Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Département d’Oncologie médicale, Institut Claudius Regaud, IUCT - Oncopole,
Abstract
TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab vs best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum.Org: Gustave-Roussy Cancer Campus, Institut Claudius Regaud, IUCT-Oncopole Toulouse, Institut Paoli Calmettes, Biostatistic Unit, IRCCS Humanitas Research Hospital, Rozzano (Milano), Italy,
Abstract
Final analysis of the phase IB part of the LOC-R01 trial, a non-comparative randomized phase IB/II study of escalating doses of lenalidomide and ibrutinib in association with R-MPV for patients with a newly diagnosed primary central nervous system lymphoma (PCNSL).Org: Institut Curie, Saint Cloud, France, Institut Curie, Biostatistics Unit, Centre Henri-Becquerel and University of Rouen, Bergonié Institute, Neurology, Assistance Publique – Hôpitaux de Paris (APHP), Sorbonne Université, IHU, ICM, Groupe Hospitalier Pitié-Salpêtrière,